AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

Earnings season marches on, and we're here to spotlight the companies set to unveil their financial results in the next trading day. As Friday approaches, investors are eagerly anticipating reports ...

True leadership is about putting others first,” said Jason B. Daly, chief legal officer of Amneal Pharmaceuticals.

Poway’s Twelve Days of Festivities for adults 50 years-plus is wrapping up by creating a community memory book during a free Snaps ’n’ Scraps activity from 1 to 3 p.m. Thursday, Jan. 30 at the Mickey ...

While the Chicago metropolitan area is not a major life sciences hub, a recent Cushman & Wakefield report predicts the Chicago market should be a growth spot in the coming years. Chicago Biomedical ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...